Clinical trials: HSCT
Myelodysplastic Syndromes
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in low- and intermediate-risk myelodysplastic syndrome (MDS) patients who receive haploidentical hematopoietic stem cell transplantation…
- Trial name
- NCT03412266
- Testing
- Cytarabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma, Non-Hodgkin Lymphoma
Music Therapy on Nausea and Pain for Autologous Stem Cell
Autologous stem cell transplant (ASCT) is an important therapy for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. It has been shown to improve progression free survival and overall survival.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT01487031
- Testing
- Music Therapy, No music therapy
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Case Comprehensive Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
- Trial name
- NCT07703657
- Testing
- Rituximab (Arm A), Standard Post-Transplant Supportive Care
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Yang Donglin
Acute Leukemia in Remission, Myelodysplastic Syndromes
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
Study Design: To evaluate the efficacy of the combination of sirolimus and tacrolimus as a graft-versus-host disease prophylaxis, the investigators are going to perform a phase II, multicenter clinical trial after human leukocyte…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Accelerated-Phase
- Trial name
- NCT01488253
- Testing
- Sirolimus, Tacrolimus
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- The Korean Society of Blood and Marrow Transplantation
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma, Hodgkin's Disease
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
By doing this study, researchers hope to learn the following: The safety of hyperbaric oxygen administration in the setting of the autologous transplant The effects of hyperbaric oxygen administration on neutrophil count recovery…
- Conditions
- Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- Auto-HBO (NCT02087657)
- Testing
- Administration of hyperbaric oxygen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Relapsed Hematologic Malignancy
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the…
- Trial name
- Haplo-CIK (NCT03821519)
- Testing
- donor-derived CIK cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Leukemia, Lymphoma, Non-Hodgkin
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
- Trial name
- NCT00350181
- Testing
- Sirolimus, MMF, BCNU
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Stem Cell Transplant Complications, Delirium
Delirium in Children Undergoing Stem Cell Transplantation
Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes.
- Trial name
- NCT04937400
- Testing
- Daily screening for delirium
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,040 people
- Sponsor
- Weill Medical College of Cornell University
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Engraftment Syndrome, Allo-HSCT
Prospective Validation of Engraftment Syndrome Phenotypes and Outcomes After Hematopoietic Stem Cell Transplantation
Engraftment syndrome (ES) is an early inflammatory complication after hematopoietic stem cell transplantation (HSCT) and has been associated with subsequent transplant-related complications and adverse clinical outcomes.
- Trial name
- ES after HSCT (NCT07577375)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 250 people
- Sponsor
- Xiao Hui Zhang
Hematopoietic Stem Cell Transplantation
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
This is an investigator-initiated clinical trial to analysis melphalan pharmacokinetics in pediatric hematopoietic stem cell transplantation patients.
- Trial name
- NCT04937634
- Testing
- Melphalan
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Leukemia
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002945
- Testing
- aldesleukin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Sclerosis
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
- Trial name
- TRANSPLANTPRO (NCT06267781)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant
The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients
Patients undergoing hematopoietic stem cell transplantation (HCT) often continue to experience anxiety, depression, isolation, and other psychosocial distress due to the severe nature of the transplant experience.
- Conditions
- Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System
- Trial name
- NCT04275830
- Testing
- Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Arizona State University
Allogeneic Hematopoietic Cell Transplantation
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT05501756
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Graft -Versus-host-disease, aGVHD
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
- Trial name
- NCT07246031
- Testing
- BPC-2001
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- BioPhoenix Co., Ltd.
Graft Vs Host Disease
Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation
Twenty-four (2 x 12) patients with intestinal graft versus host disease (GVHD) Grades 2, 3 or 4 will be treated with budesonide 3mg three times daily or placebo for 12 weeks.
- Trial name
- NCT00128739
- Testing
- Budesonide
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Rafa Laboratories